Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.940
+0.090 (1.86%)
Oct 7, 2026, 10:37 AM EDT - Market open
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $243.75K in the quarter ending June 30, 2026, with 48.97% growth. This brings the company's revenue in the last twelve months to $8.02M, up 1,793.76% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth.
Revenue (ttm)
$8.02M
Revenue Growth
+1,793.76%
P/S Ratio
14.19
Revenue / Employee
$1,002,393
Employees
8
Market Cap
115.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 36.74M |
| LENZ Therapeutics | 21.48M |
| Seer, Inc. | 14.22M |
| Cibus | 4.35M |
| Inovio Pharmaceuticals | 65.34K |
| Genelux | 8.00K |
COYA News
- 2 days ago - Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302 - TheFly
- 2 days ago - Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 22 days ago - Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial - TheFly
- 22 days ago - Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 4 weeks ago - Coya announces publication of preclinical study on effects of COYA 303 - TheFly
- 4 weeks ago - Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - Business Wire
- 5 weeks ago - Coya Therapeutics Slides: Investor presentation - Filings
- 1 month ago - Coya Therapeutics reports Q2 EPS (28c), consensus (36c) - TheFly